Feb 14, 2024, 19:39
Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits
Bishal Gyawali, Associate Professor and Medical Oncologist at
“Read the news that NALIRIFOX got approved today by the FDA. Don’t be misled to believe that this represents any innovation. This is a pseudo-innovation for which you get to pay more without any added benefits. We discuss this and other pancreatic cancer treatments in our recent The Lancet Oncology essay.”
Proceed to the essay.
Source: Bishal Gyawali/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 19, 2024, 10:18
Nov 19, 2024, 10:05
Nov 19, 2024, 09:53
Nov 19, 2024, 09:44
Nov 19, 2024, 09:40
Nov 19, 2024, 09:28